P49841

PTMD Annotation Information


※ Protein Information

Tag Content
UniProt Accession GSK3B_HUMAN; P49841;
Entrez ID 2932
GenBank Protein ID NM_001146156.1; NM_002093.3;
GenBank Nucleotide ID NP_001139628.1; NP_002084.2;
Protein Name Glycogen synthase kinase-3 beta (GSK-3 beta) (EC 2.7.11.26) (Serine/threonine-protein kinase GSK3B) (EC 2.7.11.1)
Gene Name GSK3B
Organism Homo sapiens
NCBI Taxa ID 9606
Functional DescriptionConstitutively active protein kinase that acts as a negative regulator in the hormonal control of glucose homeostasis, Wnt signaling and regulation of transcription factors and microtubules, by phosphorylating and inactivating glycogen synthase (GYS1 or GYS2), EIF2B, CTNNB1/beta-catenin, APC, AXIN1, DPYSL2/CRMP2, JUN, NFATC1/NFATC, MAPT/TAU and MACF1. Requires primed phosphorylation of the majority of its substrates. In skeletal muscle, contributes to insulin regulation of glycogen synthesis by phosphorylating and inhibiting GYS1 activity and h(view all)
Sequence
(Fasta)
MSGRPRTTSF AESCKPVQQP SAFGSMKVSR DKDGSKVTTV VATPGQGPDR PQEVSYTDTK 60
VIGNGSFGVV YQAKLCDSGE LVAIKKVLQD KRFKNRELQI MRKLDHCNIV RLRYFFYSSG 120
EKKDEVYLNL VLDYVPETVY RVARHYSRAK QTLPVIYVKL YMYQLFRSLA YIHSFGICHR 180
DIKPQNLLLD PDTAVLKLCD FGSAKQLVRG EPNVSYICSR YYRAPELIFG ATDYTSSIDV 240
WSAGCVLAEL LLGQPIFPGD SGVDQLVEII KVLGTPTREQ IREMNPNYTE FKFPQIKAHP 300
WTKVFRPRTP PEAIALCSRL LEYTPTARLT PLEACAHSFF DELRDPNVKL PNGRDTPALF 360
NFTTQELSSN PPLATILIPP HARIQAAAST PTNATAASDA NTGDRGQTNN AASASASNST 420
421

※ PTM-Disease Association

NumPTMDiseaseCell TypeTypePTM SitePMID
1PhosphorylationOral squamous cell carcinomaD23723304
[Reference]: Survival curves show that the survival of patients with high Id-1, p-Akt, p-GSK3? and p-HSF1 expression was significantly worse than those with low Id-1, p-Akt, p-GSK3? and p-HSF1 expression (p=0.000)
2PhosphorylationSmall cell lung cancer/carcinomaD17972518
[Reference]: The P-GSK3beta-ser9 expression was highest in adenocarcinoma (AD) and lowest in small cell carcinomas (SCC), compared with other types of lung carcinoma (p<0.05)
3PhosphorylationAdenocarcinomaU17972518
[Reference]: The P-GSK3beta-ser9 expression was highest in adenocarcinoma (AD) and lowest in small cell carcinomas (SCC), compared with other types of lung carcinoma (p<0.05)
4PhosphorylationHepatocellular carcinoma/Hepatocarcinoma/Hepatomatumor tissueU23432902
[Reference]: The phosphorylation of GSK3? was up-regulated in cirrhotic patients with hepatocellular carcinoma (HCC) vs. patients without tumour (P < 0.05)
5Serine PhosphorylationDiabetes mellitusDS915033922
[Reference]: Most interestingly, we found that decreased pS21-GSK-3alpha and pS9-GSK-3beta phosphorylation, which is an index of GSK activation, positively correlated with the generation of brain C-terminal fragment (CTF)-gamma cleavage product of amyloid precursor protein, an index of gamma-secretase activity, in the brain of insulin-resistant relative to normoglycemic Tg2576 mice.?
6Serine PhosphorylationPancreatic cancer/carcinoma/adenocarcinomatumor tissueDS923408967
[Reference]: Pancreatic cancer cells showed higher basal levels of GSK3? and the Y216-phosphorylated active form (p-GSK3?Y216) and lower levels of the S9-phosphorylated inactive form (p-GSK3?S9) compared to HEK 293 cells
7Serine PhosphorylationLiver cancercell linePS923325562
[Reference]: Activation of AMP-activated protein kinase and phosphorylation of glycogen synthase kinase3 mediate ursolic acid induced apoptosis in HepG2 liver cancer cells
8Serine PhosphorylationLung cancer/carcinomacell linePS923149922; 23514933
[Reference]: Blocking IL17A reduces the expression of BCL2 and promotes the interaction of BCL2 and GSK3B in BLM-induced fibrotic lung tissue
9Serine PhosphorylationOvarian cancer/carcinomacell linePS923667667
[Reference]: Huaier queous extract inhibits ovarian cancer cell motility via the AKT/GSK3?/-catenin pathway
10Serine PhosphorylationGastric cancertumor tissuePS923123500
[Reference]: PI3K/Akt-dependent phosphorylation of GSK3? and activation of RhoA regulate Wnt5a-induced gastric cancer cell migration
11Serine PhosphorylationMajor depressive disorderUS922622071
[Reference]: Depressed patients had significantly higher levels of pGSK3B as compared to controls (p < 0.001).
12Serine PhosphorylationSquamous cell carcinomaUS918606491
[Reference]: In a mouse epidermal multistage carcinogenesis model, a dramatic increase in pGSK3(Ser9) (inactive form of GSK3?) is observed in late papillomas and squamous cell carcinomas, while a significant decrease in pGSK3(Tyr216) (active form of GSK3b) is detected in squamous cell carcinoma samples compared to normal tissues; this indicates an inactivation of GSK3? occurs during mouse skin carcinogenesis
13Serine PhosphorylationPapillomasUS918606491
[Reference]: In a mouse epidermal multistage carcinogenesis model, a dramatic increase in pGSK3(Ser9) (inactive form of GSK3?) is observed in late papillomas and squamous cell carcinomas, while a significant decrease in pGSK3(Tyr216) (active form of GSK3?) is detected in squamous cell carcinoma samples compared to normal tissues; this indicates an inactivation of GSK3? occurs during mouse skin carcinogenesis
14Serine PhosphorylationSkin cancerUS918606491
[Reference]: In a mouse epidermal multistage carcinogenesis model, a dramatic increase in pGSK3(Ser9) (inactive form of GSK3?) is observed in late papillomas and squamous cell carcinomas, while a significant decrease in pGSK3(Tyr216) (active form of GSK3?) is detected in squamous cell carcinoma samples compared to normal tissues; this indicates an inactivation of GSK3? occurs during mouse skin carcinogenesis
15Serine PhosphorylationBreast cancer/tumor/carcinomaUS917495324; 27494834
[Reference]: Inactivation of GSK3? as measured by its phosphorylation at Ser9 is positively correlated with higher level of H3K27 trimethylation in tumor tissues from breast cancer patients.?
16Serine PhosphorylationSystemic lupus erythematosusUS923735868
[Reference]: Pretreatment with NaHS decreased PHA-induced expression of CDK2, phosphorylation levels of AKT (ser473) and GSK3? (ser9) and increased the expression of p27(Kip1) and p21(WAF1/CIP1)
17Serine PhosphorylationBipolar disorderUS916806104
[Reference]: The level of phospho-Ser9-GSK3beta in PBMCs was regulated by agents that modified kinases and phosphatases acting on GSK3beta and was increased by in vitro lithium treatment.?
18Serine PhosphorylationLymphomaUS920224723
[Reference]: We recently reported that mantle cell lymphoma (MCL) frequently shows evidence of GSK-3beta inactivation, since GSK-3beta is phoshorylated at its functionally critical serine 9 residue in all MCL cell lines and the majority of MCL tumors examined.
19Tyrosine PhosphorylationSquamous cell carcinomaDY21618606491
[Reference]: In a mouse epidermal multistage carcinogenesis model, a dramatic increase in pGSK3(Ser9) (inactive form of GSK3?) is observed in late papillomas and squamous cell carcinomas, while a significant decrease in pGSK3(Tyr216) (active form of GSK3) is detected in squamous cell carcinoma samples compared to normal tissues; this indicates an inactivation of GSK3 occurs during mouse skin carcinogenesis
20Tyrosine PhosphorylationBreast cancer/tumor/carcinomacell linePY21623565238
[Reference]: CG0009 enhanced the inactivating phosphorylation of GSK3? at Ser21 and GSK3? at Ser9 and simultaneously decreased activating phosphorylation of GSK3? at Tyr216, and induced caspase-dependent apoptosis independently of estrogen receptor (ER) expression status
21Tyrosine PhosphorylationNeuroblastomaUY21624349301
[Reference]: Increased in NB10 cells (MYCN amplified neuroblastoma line) compared to NPC cells (normal neural crest line)
22Tyrosine PhosphorylationPancreatic cancer/carcinoma/adenocarcinomatumor tissueUY21623408967
[Reference]: Pancreatic cancer cells showed higher basal levels of GSK3 and the Y216-phosphorylated active form (p-GSK3?Y216) and lower levels of the S9-phosphorylated inactive form (p-GSK3S9) compared to HEK 293 cells

※ Disease Cross-ref Annotation

DatabaseAnnotation
CTD (Curated)
(count: 20)
(view all)
MESH:D000015 ; Abnormalities, Multiple
MESH:D058186 ; Acute Kidney Injury
MESH:D000544 ; Alzheimer Disease
MESH:D001169 ; Arthritis, Experimental
MESH:D001714 ; Bipolar Disorder
MESH:D001930 ; Brain Injuries
DisGeNet (Curated)
(count: 18)
(view all)
C0002395; Alzheimer's Disease
C0005586; Bipolar Disorder
C0011570; Mental Depression
C0011581; Depressive disorder
C0018800; Cardiomegaly
C0018801; Heart failure
HGMD
(count: 4)
CN077128; Bipolar disorder, association with; Gross insertions
CR044970; Bipolar disorder, age of onset, assoc. with; Regulatory
CS084695; Alzheimer disease, association with; Splicing
CS054900; Parkinson's disease, risk, association with; Splicing
GWASdb
(count: 12)
(view all)
rs16830551; HDL cholesterol; cholesterol ester storage disease|cholesterol embolism|coronary artery disease
rs16830551; LDL cholesterol; atherosclerosis|coronary artery disease
rs6808874; Drug response to Citalopram; Null
rs6808874; Drug response to Fluoxetine; Null
rs6805251; HDL cholesterol; cholesterol ester storage disease|cholesterol embolism|coronary artery disease
rs2319398; Drug response to Citalopram; Null

※ PTM Sites

PTM Modification Sites
Phosphorylation
(count: 28)
(view all)
13        RTTSFAESCKPVQQP     dbPAF
2         ******MSGRPRTTS     dbPAF
21        CKPVQQPSAFGSMKV     dbPAF
215       VRGEPNVSYICSRYY     dbPAF
216       RGEPNVSYICSRYYR     dbPAF
219       PNVSYICSRYYRAPE     dbPAF
Acetylation
(count: 1)
15        TSFAESCKPVQQPSA     PLMD
Ubiquitination
(count: 4)
15        TSFAESCKPVQQPSA     PLMD
183       GICHRDIKPQNLLLD     PLMD
349       ELRDPNVKLPNGRDT     PLMD
86        GELVAIKKVLQDKRF     PLMD
Sumoylation
(count: 1)
292       NPNYTEFKFPQIKAH     PLMD
Glycation
(count: 1)
27        PSAFGSMKVSRDKDG     PLMD

※ Protein-Protein Interaction

NetworkInteraction
ABSource
A5PL33P49841IntAct
A5YKK6P49841BioGRID
A6NIX2P49841MINT
C9JL81P49841BioGRID
E5RGJ7P49841IntAct
E7ENH9P49841IntAct
E9PE71P49841BioGRID
F8W0C3P49841BioGRID
G5E9Y2P49841MINT
H0Y2T6P49841BioGRID
H0YBT0P49841IntAct
H0YG33P49841MINT
H0YLL2P49841BioGRID
H3BP91P49841BioGRID
O00571P49841IntAct
O14908P49841MINT
O15169P49841DIP; IntAct; MINT;HPRD
O15294P49841HPRD
O43194P49841MINT
O43427P49841MINT
O43709P49841BioGRID
O60502P49841MINT
O60716P49841HPRD
O75165P49841MINT
O75354P49841MINT
O75398P49841IntAct
O75448P49841MINT
O75533P49841IntAct
O75689P49841MINT
O75935P49841MINT
O94805P49841MINT
O94811P49841HPRD
O95163P49841IntAct
O95182P49841BioGRID
O95377P49841MINT
O95863P49841IntAct; MINT;HPRD
P00441P49841BioGRID
P01106P49841DIP
P01266P49841BioGRID
P01733P49841BioGRID
P01871P49841MINT
P03897P49841BioGRID
P03973P49841BioGRID
P04198P49841IntAct
P04406P49841BioGRID; MINT
P04637P49841MINT;HPRD
P05000P49841BioGRID
P05023P49841BioGRID
P05093P49841BioGRID
P05386P49841MINT
P05412P49841DIP
P05452P49841MINT
P05771P49841BioGRID
P07108P49841MINT
P07199P49841MINT
P08621P49841IntAct
P08670P49841MINT
P09629P49841BioGRID
P0CF51P49841BioGRID
P10242P49841BioGRID
P10275P49841HPRD
P10636P49841MINT
P11217P49841BioGRID
P12268P49841IntAct
P12821P49841BioGRID
P13611P49841BioGRID
P13807P49841IntAct; MINT
P15428P49841BioGRID
P15880P49841MINT
P15941P49841HPRD
P16220P49841HPRD
P16989P49841MINT
P17252P49841BioGRID
P17844P49841IntAct
P18031P49841MINT
P18505P49841BioGRID
P19793P49841MINT
P20264P49841BioGRID
P21246P49841MINT
P22492P49841IntAct
P23246P49841BioGRID
P23771P49841BioGRID
P24941P49841BioGRID
P25054P49841HPRD
P26358P49841MINT
P26368P49841BioGRID
P26641P49841MINT
P27816P49841MINT
P29034P49841BioGRID
P30876P49841IntAct
P31749P49841DIP; IntAct;HPRD
P31751P49841IntAct;HPRD
P32456P49841MINT
P33176P49841MINT
P33552P49841BioGRID
P35222P49841IntAct; MINT;HPRD
P35637P49841IntAct
P37840P49841MINT
P39748P49841MINT
P41236P49841MINT
P42345P49841MINT
P46531P49841HPRD
P47897P49841MINT
P48740P49841MINT
P49715P49841HPRD
P49768P49841MINT;HPRD
P49841P50748BioGRID
P49841P51531IntAct
P49841P51659IntAct
P49841P51668MINT
P49841P52742MINT
P49841P54252MINT
P49841P55771BioGRID
P49841P57678IntAct
P49841P59665MINT
P49841P61960MINT
P49841P61968MINT
P49841P62879MINT
P49841P62979BioGRID
P49841P67775MINT
P49841P67809MINT
P49841P68104MINT
P49841Q00013MINT
P49841Q01094HPRD
P49841Q01201IntAct
P49841Q01844IntAct
P49841Q02817BioGRID
P49841Q03692BioGRID
P49841Q03701MINT
P49841Q04206IntAct
P49841Q04724MINT
P49841Q06330MINT
P49841Q07812DIP
P49841Q07820HPRD
P49841Q08752DIP
P49841Q12778HPRD
P49841Q12873MINT
P49841Q12933IntAct
P49841Q13163IntAct
P49841Q13239MINT
P49841Q13467MINT
P49841Q13541MINT
P49841Q13794MINT
P49841Q14134IntAct
P49841Q14147MINT
P49841Q14203HPRD
P49841Q14562BioGRID
P49841Q15029MINT
P49841Q15404MINT
P49841Q15459IntAct
P49841Q15797IntAct
P49841Q15828MINT
P49841Q15847MINT
P49841Q16555HPRD
P49841Q16637IntAct
P49841Q16877MINT
P49841Q2T9K0MINT
P49841Q58A44BioGRID
P49841Q5W0B1IntAct
P49841Q6NUN9MINT
P49841Q6UN15IntAct
P49841Q6UUV7BioGRID
P49841Q6UXH1MINT
P49841Q71DI3BioGRID
P49841Q71U36MINT
P49841Q75N90MINT
P49841Q7L266MINT
P49841Q7Z5J4MINT
P49841Q86WZ6MINT
P49841Q8IUE6BioGRID
P49841Q8IWV7MINT
P49841Q8IX07IntAct
P49841Q8N0Z3IntAct
P49841Q8N205MINT
P49841Q8N4C6IntAct
P49841Q8TDN6MINT
P49841Q8TDZ2MINT
P49841Q8WWQ8BioGRID
P49841Q92945MINT
P49841Q969Q0MINT
P49841Q96A73MINT
P49841Q96BR1IntAct
P49841Q96G01MINT
P49841Q96GR2MINT
P49841Q96HA7MINT
P49841Q96ID5MINT
P49841Q96QU8IntAct
P49841Q99626HPRD
P49841Q99929BioGRID
P49841Q99956IntAct
P49841Q9BTE0MINT
P49841Q9BZV1MINT
P49841Q9H095MINT
P49841Q9H1J1IntAct
P49841Q9H254MINT
P49841Q9H2U1IntAct
P49841Q9H4H8MINT
P49841Q9H7B2IntAct
P49841Q9HBH7MINT
P49841Q9HBR0BioGRID
P49841Q9NP79IntAct
P49841Q9NPA3MINT
P49841Q9NRG4IntAct
P49841Q9NWM8MINT
P49841Q9NXS2IntAct
P49841Q9NZI8IntAct
P49841Q9P0R6IntAct
P49841Q9P1W9MINT
P49841Q9P1Y5MINT
P49841Q9UBL3BioGRID
P49841Q9UHI6IntAct
P49841Q9UHR5MINT
P49841Q9UHY1MINT
P49841Q9UID3MINT
P49841Q9UII2MINT
P49841Q9UJW3MINT
P49841Q9UKR5MINT
P49841Q9UKY1MINT
P49841Q9UMD9BioGRID
P49841Q9UNZ2MINT
P49841Q9Y383MINT
P49841Q9Y3F4IntAct
P49841Q9Y483MINT
P49841Q9Y600MINT
P49841Q9Y6E2MINT
P49841Q9Y6I7MINT